Genomic analyses of localized, non-indolent prostate cancer identify recurrent aberrations that can predict relapse, and also highlight differences between early prostate cancer and metastatic, castration-resistant disease.
- Michael Fraser
- Veronica Y. Sabelnykova
- Paul C. Boutros